Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Dyve Biosciences General Information
Completed a successful Phase 2 study in 2022 with DYV700, which met its clinically relevant endpoint of reducing pain caused by the acidic microenvironment of acute gouty arthritis. Preclinical data for DYV800 (oncology candidate) was presented at the American Association for Cancer Research 2023 Annual Meeting.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Camarillo, California
United States
United States
Drug Pipeline
DYV800
Pre-clinicalKey Partnerships
H. Lee Moffitt Cancer Center & Research Institute
Dyve Biosciences Funding
No funding data available
To view Dyve Biosciences's complete valuation and funding history, request access »